{
  "thread": {
    "uuid": "29b7ca9e6623e6068ea549943b34f23465bba26d",
    "url": "https://investorshangout.com/tenaya-therapeutics-advances-gene-therapy-program-for-hcm-82861-",
    "site_full": "investorshangout.com",
    "site": "investorshangout.com",
    "site_section": "https://investorshangout.com/disclaimer ",
    "site_categories": [
      "stocks",
      "finance",
      "options"
    ],
    "section_title": "Investors Hangout - Free Stock Message Boards, NASDAQ, NYSE, OTC, Penny Stocks, Stock Charts, Stock Quotes, News",
    "title": "Tenaya Therapeutics Advances Gene Therapy Program for HCM",
    "title_full": "Tenaya Therapeutics Advances Gene Therapy Program for HCM",
    "published": "2024-10-17T23:46:00.000+03:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "US",
    "main_image": "https://investorshangout.com/images/blog/ihnews-Tenaya%20Therapeutics%20Advances%20Gene%20Therapy%20Program%20for%20HCM.jpg",
    "performance_score": 0,
    "domain_rank": 108773,
    "domain_rank_updated": "2024-10-15T00:00:00.000+03:00",
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "29b7ca9e6623e6068ea549943b34f23465bba26d",
  "url": "https://investorshangout.com/tenaya-therapeutics-advances-gene-therapy-program-for-hcm-82861-",
  "ord_in_thread": 0,
  "parent_url": null,
  "author": "Addison Perry",
  "published": "2024-10-17T23:46:00.000+03:00",
  "title": "Tenaya Therapeutics Advances Gene Therapy Program for HCM",
  "text": "Tenaya Therapeutics Advances Gene Therapy Program for HCM [Addison Perry](https://investorshangout.com/profile/view?id=79055)Updated: 10-17-2024 04:46 PM Update on TN-201 Gene Therapy for HCM Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a pioneering clinical-stage biotechnology company, is excited to announce the recent progress in its TN-201 gene therapy program aimed at treating hypertrophic cardiomyopathy (HCM) linked to the MYBPC3 gene. Phase 1b/2 MyPEAK-1 clinical trial of TN-201 is currently underway, and it aims to provide an innovative solution to a complex heart condition characterized by its genetic basis. Significant Trial Progress In a welcome update, the Independent Data Safety and Monitoring Board (DSMB) has recommended advancing the trial's dosage and has endorsed an expansion of eligibility criteria. This pivotal decision highlights the encouraging safety profile of TN-201 in its current dosage of 3E13 vg/kg, as no unexpected side effects have been reported thus far. Whit Tingley, M.D., Ph.D., Tenaya’s Chief Medical Officer, emphasizes how this decision presents an optimistic outlook for the therapy's overall safety and potential application in wider patient demographics. Enrollment Updates and Protocol Adjustments The trial has successfully completed the initial dosing for three patients in Cohort 1, all documenting favorable tolerability outcomes. Building on these findings, Tenaya is now progressing into Cohort 2, where participants will receive the higher 6E13 vg/kg dosage. Several refinements to the study protocols have been set in place to enhance the research's efficacy and comprehensiveness, including the addition of more cardiac biopsies and recruiting adults with both obstructive and nonobstructive forms of HCM. Insights into Pediatrics and HCM Disease Burden As part of its commitment to understanding the implications of MYBPC3-associated HCM, Tenaya has been collecting important data on pediatric populations, including insights presented by Dr. Tingley at a significant medical conference. From a database including nearly 1,800 individuals with MYBPC3-linked HCM, it was found that around 13% were diagnosed before age 18, indicating the critical need for early intervention and innovative therapies. Challenges Faced by Young Patients The findings highlight a concerning statistic: 50% of pediatric patients can face serious health challenges by the age of 40. These trends underline the ongoing need for genetic therapies that focus on not just adult populations but also on young patients with this serious condition, thereby emphasizing Tenaya’s mission of providing life-altering treatments for all age groups. What’s Next for TN-201? The upcoming reporting of initial data from Cohort 1 is highly anticipated. Set to be unveiled later, it will focus on safety evaluations, tolerability analysis, and biochemical changes post-treatment. The MyPEAK-1 trial continues to collect fascinating data on imaging biomarkers and how TN-201 impacts heart function and quality of life for patients. This could steer future developments of genetic medicines that significantly benefit patients suffering from MYBPC3-associated HCM. Tenaya’s Commitment and Future Prospects Tenaya Therapeutics is determined to leverage its cutting-edge research capabilities to not only advance TN-201 but also expand its pipeline. This includes potential therapies for other cardiomyopathies and heart-related conditions. As the company moves forward, all eyes will be on the outcomes of the MyPEAK-1 trial, which could pave the way for more substantial breakthroughs in genetic therapy aimed at heart disease. Frequently Asked Questions What is TN-201? TN-201 is a gene therapy aimed at increasing MyBP-C protein levels to treat MYBPC3-associated HCM, utilizing a single intravenous infusion. What recent advancements have been made in the clinical trial? Tenaya has successfully completed Cohort 1 dosing and is moving forward with Cohort 2, expanding eligibility criteria and monitoring protocols. When will the initial data from Cohort 1 be reported? Initial data from Cohort 1 is expected to be reported soon, focusing on safety and tolerability of TN-201. Why are pediatric insights important for HCM? Pediatric insights emphasize the prevalence of HCM diagnoses in youth and highlight the need for early therapeutic interventions. What is Tenaya Therapeutics' mission? Tenaya's mission is to discover and deliver innovative therapies that target the underlying causes of heart disease, focusing on genetic disorders. About Investors Hangout [Investors Hangout](https://investorshangout.com/) is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: [https://investorshangout.com/](https://investorshangout.com/) Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it \"as is.\" Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please [contact us](https://investorshangout.com/contact) for corrections. Related Articles - [Brinker International, Inc. to Host Earnings Call for Q1 2025](/brinker-international-inc-to-host-earnings-call-for-q1-2025-82946-/) - [Act Now: Class Action Suit for Paragon 28, Inc. Investors](/act-now-class-action-suit-for-paragon-28-inc-investors-82927-/) - [SWK Holdings Prepares for Q3 Earnings and Portfolio Updates](/swk-holdings-prepares-for-q3-earnings-and-portfolio-updates-82925-/) - [Synaptics to Present First Quarter Results for Fiscal 2025](/synaptics-to-present-first-quarter-results-for-fiscal-2025-82923-/) - [South Plains Financial Boosts Cash Dividend by 7% for Investors](/south-plains-financial-boosts-cash-dividend-by-7-for-investors-82917-/) - [Joint Efforts for Affordable Housing: Greystone and BlackRock Unite](/joint-efforts-for-affordable-housing-greystone-and-blackrock-unite-82914-/) - [Lincoln Electric Boosts Dividend and Leadership for Growth](/lincoln-electric-boosts-dividend-and-leadership-for-growth-82913-/) - [Tenaya Therapeutics Advances Gene Therapy for Heart Health](/tenaya-therapeutics-advances-gene-therapy-for-heart-health-82911-/) - [Rural Development Partners and ERMCO: A Strategic Alliance for Growth](/rural-development-partners-and-ermco-a-strategic-alliance-for-growth-82905-/) - [Con Edison Announces Quarterly Dividend for Shareholders](/con-edison-announces-quarterly-dividend-for-shareholders-82898-/) Recent Articles - [Semrush Holdings, Inc. Scheduled Conference Call for Q3 2024](/semrush-holdings-inc-scheduled-conference-call-for-q3-2024-82860-/) - [Bandwidth Inc. Set to Discuss Third Quarter Financials Soon](/bandwidth-inc-set-to-discuss-third-quarter-financials-soon-82859-/) - [AYR Wellness Announces Third Quarter Conference Call Details](/ayr-wellness-announces-third-quarter-conference-call-details-82858-/) - [United Bancshares Reports Impressive Q3 2024 Financial Gains](/united-bancshares-reports-impressive-q3-2024-financial-gains-82857-/) - [Exciting Announcements Ahead for Cinemark's Q3 2024 Earnings](/exciting-announcements-ahead-for-cinemarks-q3-2024-earnings-82856-/) - [Goosehead Insurance Set to Reveal Q3 2024 Financial Performance](/goosehead-insurance-set-to-reveal-q3-2024-financial-performance-82855-/) - [Lincoln Electric Boosts Dividend Amid Strong Business Performance](/lincoln-electric-boosts-dividend-amid-strong-business-performance-82854-/) - [Celebrate the Joy of Sunber Hair’s 7th Anniversary Sale](/celebrate-the-joy-of-sunber-hairs-7th-anniversary-sale-82853-/) - [Customers Bancorp Sets Date for Third Quarter 2024 Earnings Call](/customers-bancorp-sets-date-for-third-quarter-2024-earnings-call-82852-/) - [Crown Holdings Sees Growth Amid Financial Challenges](/crown-holdings-sees-growth-amid-financial-challenges-82851-/) - [Sealed Air Announces Quarterly Dividend Contribution for Shareholders](/sealed-air-announces-quarterly-dividend-contribution-for-shareholders-82850-/) - [BlackSky Plans Q3 2024 Results Call to Discuss Insights](/blacksky-plans-q3-2024-results-call-to-discuss-insights-82849-/) - [Better Home & Finance Holding Company Prepares Third Quarter Report](/better-home-finance-holding-company-prepares-third-quarter-report-82848-/) - [Huntington Bancshares Increases Cash Dividends for 2025](/huntington-bancshares-increases-cash-dividends-for-2025-82847-/) - [SolarWinds Prepares for Q3 2024 Financial Results Announcement](/solarwinds-prepares-for-q3-2024-financial-results-announcement-82846-/) - [Centrus Energy Advances Domestic Uranium Enrichment Initiatives](/centrus-energy-advances-domestic-uranium-enrichment-initiatives-82845-/) - [Intuitive Surgical Reports Strong Q3 Performance and Growth](/intuitive-surgical-reports-strong-q3-performance-and-growth-82844-/) - [NYSE American Initiates Delisting of Calidi Biotherapeutics Warrants](/nyse-american-initiates-delisting-of-calidi-biotherapeutics-warrants-82843-/) - [Quaker Houghton Schedules Earnings Call for Q3 2024](/quaker-houghton-schedules-earnings-call-for-q3-2024-82842-/) - [AYR Wellness Announces Q3 2024 Earnings Call Details](/ayr-wellness-announces-q3-2024-earnings-call-details-82841-/) - [Genpact Limited Announces Exciting Dividend for Stakeholders](/genpact-limited-announces-exciting-dividend-for-stakeholders-82840-/) - [United Bancshares Reports Strong Q3 2024 Performance](/united-bancshares-reports-strong-q3-2024-performance-82839-/) - [Ansys Announces Upcoming Earnings Release - Q3 2024 Expectations](/ansys-announces-upcoming-earnings-release-q3-2024-expectations-82838-/) - [McCormick & Company: Key Insights from Upcoming Investor Day](/mccormick-company-key-insights-from-upcoming-investor-day-82837-/) - [Investor Alert: Fortrea Holdings Inc. Faces Investigative Scrutiny](/investor-alert-fortrea-holdings-inc-faces-investigative-scrutiny-82836-/) - [Patrick Industries Prepares for Q3 2024 Earnings Conference Call](/patrick-industries-prepares-for-q3-2024-earnings-conference-call-82835-/) - [Regency Affiliates Strengthens Position with 331,500 Share Buyback](/regency-affiliates-strengthens-position-with-331500-share-buyback-82834-/) - [Little Sunshine's Playhouse Expands in Denver Metro Area](/little-sunshines-playhouse-expands-in-denver-metro-area-82833-/) - [Richmond American Homes Celebrates Grand Opening of Timberline](/richmond-american-homes-celebrates-grand-opening-of-timberline-82832-/) - [ALICORN Enhances Access to Virtual Primary Care Services](/alicorn-enhances-access-to-virtual-primary-care-services-82831-/) - [VIAVI Solutions Set to Reveal Fiscal Q1 2025 Financials Soon](/viavi-solutions-set-to-reveal-fiscal-q1-2025-financials-soon-82830-/) - [Investigation Underway for Stitch Fix, Inc. Shareholders](/investigation-underway-for-stitch-fix-inc-shareholders-82829-/) - [Hanford Tank Waste Operations & Closure Begins Cleanup Efforts](/hanford-tank-waste-operations-closure-begins-cleanup-efforts-82828-/) - [Exciting Game Reveals from Xbox Partner Preview Event](/exciting-game-reveals-from-xbox-partner-preview-event-82827-/) - [Fastenal Appoints New EVP of Strategy to Boost Growth](/fastenal-appoints-new-evp-of-strategy-to-boost-growth-82826-/) - [Cynthia McCabe Steps Up as Exelon's Senior VP and Chief Officer](/cynthia-mccabe-steps-up-as-exelons-senior-vp-and-chief-officer-82825-/) - [Natalia Scherbakoff Takes Charge as Orion S.A. CTO](/natalia-scherbakoff-takes-charge-as-orion-sa-cto-82824-/) - [Integrated Power Services Expands Reach with MDL Énergie Deal](/integrated-power-services-expands-reach-with-mdl-nergie-deal-82823-/) - [Agilon Health Schedules Third Quarter 2024 Financial Call](/agilon-health-schedules-third-quarter-2024-financial-call-82822-/) - [GoHealth Shares Insights at Upcoming Investor Conference](/gohealth-shares-insights-at-upcoming-investor-conference-82821-/) - [Cohu, Inc. Plans to Discuss Financial Results Soon](/cohu-inc-plans-to-discuss-financial-results-soon-82820-/) - [Asure Software's Upcoming Q3 2024 Financial Results Announcement](/asure-softwares-upcoming-q3-2024-financial-results-announcement-82819-/) - [The Trade Desk Shares Q3 2024 Earnings Call Insights](/the-trade-desk-shares-q3-2024-earnings-call-insights-82818-/) - [Exciting Earnings Announcement from Capital Southwest Corp](/exciting-earnings-announcement-from-capital-southwest-corp-82817-/) - [Cirrus Logic Announces Upcoming Financial Results and Webcast](/cirrus-logic-announces-upcoming-financial-results-and-webcast-82816-/) - [Netflix Surfaces with Impressive Subscriber Growth this Quarter](/netflix-surfaces-with-impressive-subscriber-growth-this-quarter-82815-/) - [Arrow Electronics Sets Date for Q3 2024 Earnings Call](/arrow-electronics-sets-date-for-q3-2024-earnings-call-82814-/) - [Understanding Recent Mergers: K, AFBI, and ARC’s Path Forward](/understanding-recent-mergers-k-afbi-and-arcs-path-forward-82813-/) - [Netflix Reports Strong Growth Amidst Price Hike Anticipation](/netflix-reports-strong-growth-amidst-price-hike-anticipation-82812-/) - [Doximity Announces Fiscal 2025 Q2 Results Release Date](/doximity-announces-fiscal-2025-q2-results-release-date-82811-/)",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "english",
  "sentiment": "positive",
  "categories": [
    "Health",
    "Science and Technology",
    "Human Interest"
  ],
  "ai_allow": true,
  "webz_reporter": false,
  "external_links": [],
  "external_images": [],
  "entities": {
    "persons": [
      {
        "name": "Addison Perry",
        "sentiment": "none"
      },
      {
        "name": "Whit Tingley",
        "sentiment": "none"
      }
    ],
    "organizations": [
      {
        "name": "HCM Tenaya Therapeutics, Inc.",
        "sentiment": "none"
      }
    ],
    "locations": []
  },
  "syndication": {
    "syndicated": false,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "rating": null,
  "crawled": "2024-10-18T00:14:27.693+03:00",
  "updated": "2024-10-18T00:14:27.693+03:00"
}